For example, olaratumab is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody that received the FDA approval in 2016 for use in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma (STS) (Shirley, 2017). This evidence concerns the gene PDGFRA and soft tissue sarcoma.